Cibi e Bevande
With Over USD 3.5 Billion in Capital Investment, and Numerous High Value Licensing Deals, the Targeted Protein Degradation Market is Anticipated to Grow at an Annualized Rate of Over 30%, Claims Roots Analysis
The concept of targeted protein degradation presents revolutionary drug development opportunities and is anticipated to bring about a paradigm shift in modern healthcare. The first targeted protein degrader, called proteolysis targeting chimera (PROTAC), was developed about a decade ago. Presently, a variety of other such chemical entities and molecular glues are under investigation. In fact, certain pipeline candidates are already in the mid to late-phase trials and are anticipated to soon enter the market.
Nearly 20% of pipeline drugs are in the clinical phase of development, while the rest are in the preclinical / discovery stage. At present, PROTACs account for more than 30% of the pipeline drugs.
Most targeted protein degrader leads are being investigated for the treatment of breast cancer, colorectal cancer, and prostate cancer. This class of drugs is also being evaluated for the treatment of non-oncological indications, such as Alzheimer's disease, liver fibrosis, Parkinson's disease, psoriasis, and rheumatoid arthritis.
Centers in North America account for over 50% of the enrolled patient population; this is followed by Europe (34%) and Asia-Pacific (9%).
Partnership activity in this domain has increased at a CAGR of close to 40%. In fact, more than 60% such agreements have been signed since 2016; majority of these agreements focused on R&D and product / technology licensing.
Of this, close to USD 1.2 billion was raised through venture capital financing, representing around 35% of the total capital raised till Q3 2019. On the other hand, there were over 15 instances of IPOs / secondary offerings, accounting for more than USD 1.7 billion in financing.
With a promising development pipeline and encouraging clinical results, the market is anticipated to witness a rapid growth rate during the next decade. Interestingly, the markets in China and Japan are anticipated to grow at a relatively faster rate.
The ~USD 4.0 billion financial opportunity (by 2030) within the target protein degradation market has been analyzed across the following segments:
The report features inputs from eminent industry stakeholders, according to whom targeted protein degradation-based drugs are currently considered to be promising alternatives for the treatment of a myriad of chronic clinical indications. The report includes detailed transcripts of discussions held with the following experts:
The research covers detailed profiles, featuring a brief company overview, its financial information ( ), product portfolio details (such as status of development of pipeline candidates, clinical trial information and analysis of key trial endpoints), recent developments and an informed future outlook.
For additional details, please visit
https://www.rootsanalysis.com/reports/view_document/protein-degradation-market/289.html or email sales@rootsanalysis.com
You may also be interested in the following titles:
Gaurav Chaudhary
+1-(415)-800-3415
+44-(122)-391-1091
Gaurav.Chaudhary@rootsanalysis.com
Logo: https://mma.prnewswire.com/media/742223/Roots_Analysis_Logo.jpg